It has been found that TNF‐α can induce neutrophils of UC patients to release NETs, and the anti‐TNF‐α antibody infliximab (IFX) significantly reduced the expression of PAD4 and NETs in colon tissues of UC patients, providing support for the clinical treatment of refractory IBD with anti‐TNF‐α agents.353. Here, PADI4 is linked to inflammatory bowel disease.